CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE
✉ Email this page to a colleague
All Clinical Trials for ethinyl estradiol; ferrous fumarate; norethindrone
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01344369 ↗ | Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions | Completed | Teva Pharmaceuticals USA | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ethinyl estradiol; ferrous fumarate; norethindrone
Condition Name
Clinical Trial Locations for ethinyl estradiol; ferrous fumarate; norethindrone
Trials by Country
Clinical Trial Progress for ethinyl estradiol; ferrous fumarate; norethindrone
Clinical Trial Phase
Clinical Trial Sponsors for ethinyl estradiol; ferrous fumarate; norethindrone
Sponsor Name